Here are some updates on drug research and technology from my reading-
FDA Approves Seasonal Influenza Vaccine Fluarix for Pediatric Use
The USFDA has reportedly approved use of the seasonal influenza vaccine Fluarix for children ages 3 years to 17 years. Fluarix is a seasonal influenza vaccine not intended to protect against the 2009 H1N1 influenza virus. Further information is available at-http://www.drugs.com/newdrugs/fda-approves-seasonal-influenza-vaccine-fluarix-pediatric-use-1695.html
The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005.
Votrient is an oral medication that interferes with angiogenesis, the growth of new blood vessels needed for solid tumors to grow and survive. Votrient is intended for people with advanced renal cell carcinoma, a type of kidney cancer in which the cancerous cells are found in the lining of very small tubes (tubules) in the kidney.
FDA approves expanded indication for Micardis.
The USFDA has expanded the indication for the antihypertension drug telmisartan (Micardis), making it the first angiotensin receptor blocker approved for primary prevention in high-risk patients unable to take an ACE inhibitor. The FDA also granted new approval for Twynsta, a drug product containing telmisartan and amlodipine in combination.
FDA Approves Seasonal Influenza Vaccine Fluarix for Pediatric Use
The USFDA has reportedly approved use of the seasonal influenza vaccine Fluarix for children ages 3 years to 17 years. Fluarix is a seasonal influenza vaccine not intended to protect against the 2009 H1N1 influenza virus. Further information is available at-http://www.drugs.com/newdrugs/fda-approves-seasonal-influenza-vaccine-fluarix-pediatric-use-1695.html
The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005.
Votrient is an oral medication that interferes with angiogenesis, the growth of new blood vessels needed for solid tumors to grow and survive. Votrient is intended for people with advanced renal cell carcinoma, a type of kidney cancer in which the cancerous cells are found in the lining of very small tubes (tubules) in the kidney.
FDA approves expanded indication for Micardis.
The USFDA has expanded the indication for the antihypertension drug telmisartan (Micardis), making it the first angiotensin receptor blocker approved for primary prevention in high-risk patients unable to take an ACE inhibitor. The FDA also granted new approval for Twynsta, a drug product containing telmisartan and amlodipine in combination.
